Bloomberg
@business
The first word in business news | Watch Live: | Newsletters: | Podcasts:
Joined April 2009
104 Following 10.5M Followers
Novo Nordisk will pay as much as $2.6 billion to license an experimental obesity pill from China’s Hengrui, as it seeks to rebuild investor confidence in its future beyond blockbusters Ozempic and Wegovy
Show more
